Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Apr-Jun;6(2):215-22.
doi: 10.1111/j.1582-4934.2002.tb00188.x.

MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis

K Demopoulos  1 , D A Arvanitis, D A Vassilakis, N M Siafakas, D A Spandidos
Affiliations

MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis

K Demopoulos et al. J Cell Mol Med. 2002 Apr-Jun.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic interstitial pneumonia limited to the lung and characterized by a fibroproliferative response with only minor signs of inflammation, which almost always causes rapid fibrotic destruction of the lung. In this study, we investigated genomic instability in IPF, using microsatellite DNA analysis, aiming to detect any specific genetic alterations for this disease. We used 40 highly polymorphic microsatellite DNA markers, in multiplex PCR assays, to examine 52 sputum specimens from IPF patients versus correspondent venous blood. Loss of heterozygosity (LOH) was found in 20 (38.5%) patients in at least one locus. These alterations were found on markers previously associated with lung cancer located on 1p34.3, 3p21.32-p21.1, 5q32-q33.1, 9p21 and 17p13.1 where MYCL1, FHIT, SPARC, p16(Ink4) and TP53 genes have been mapped respectively. These data provide new insights into IPF pathogenesis and a new perspective for its correlation with lung cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gross T.J., Hunninghake G.W., Idiopathic pulmonary fibrosis, N. Engl. J. Med., 345: 517–525, 2001. - PubMed
    1. Ziesche R., Hofbauer E., Wittmann K., Petkov V., Block L.H., A preliminary study of long‐term treatment with interferon gamma‐1b and low‐dose prednisolone in patients with idiopathic pulmonary fibrosis, N. Engl. J. Med., 341: 1264–1269, 1999. - PubMed
    1. Iwai K., Mori T., Yamada N., Yamaguchi M., Hosoda Y., Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure, Am. J. Respir. Crit. Care Med., 150: 670–675, 1994. - PubMed
    1. Scott J., Johnston I., Britton J., What causes cryptogenic fibrosing alveolitis? A case‐control study of environmental exposure to dust, Br. Med. J., 301: 1015–1017, 1990. - PMC - PubMed
    1. Jakab G.J., Sequential virus infections, bacterial superinfections, and fibrogenesis, Am. Rev. Respi.r Dis., 142: 374–379, 1990. - PubMed